LLLing Liu

Ling Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ling Liu has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Hui Cao

    State Key Laboratory of Respiratory Disease for Allergy at Shenzhen University, Shenzhen Key Laboratory of Allergy & Immunology, Shenzhen University School of Medicine, Shenzhen 518061, China

    1 shared publication
  • Jiahua Lu

    State Key Laboratory of Respiratory Disease for Allergy at Shenzhen University, Shenzhen Key Laboratory of Allergy & Immunology, Shenzhen University School of Medicine, Shenzhen 518061, China

    1 shared publication
  • Junyi Wang

    College of Medicine, Southwest Jiaotong University, Chengdu

    1 shared publication
  • Miao Gong

    Department of Respirology & Allergy, Third Affiliated Hospital of Shenzhen University, Shenzhen 518020, China

    1 shared publication
  • Ruyi Yuan

    State Key Laboratory of Respiratory Disease for Allergy at Shenzhen University, Shenzhen Key Laboratory of Allergy & Immunology, Shenzhen University School of Medicine, Shenzhen 518061, China

    1 shared publication
  • Xiaojun Xiao

    Department of Respiratory Medicine and Allergy, The Third Affiliated Hospital (The Affiliated Luohu Hospital) of Shenzhen University, State Key Laboratory of Respiratory Disease Shenzhen University Division, Shenzhen University Medical School, Shenzhen University

    1 shared publication

Latest Publications

  • Open Access

    Effects of rAmb a 1-Loaded PLGA-PEG Nanoparticles in a Murine Model of Allergic Conjunctivitis

    by Hui Cao, Ling Liu, Junyi Wang, Miao Gong, Ruyi Yuan, Jiahua Lu, Xiaojun Xiao, Xiaoyu Liu

    Ambrosia artemisiifolia (Amb a) contains many allergens. Allergic conjunctivitis caused by Ambrosia artemisiifolia and its related allergen-specific immunotherapy (AIT) are seldom studied at present. poly(DL-lactide-co-glycolide)-polyethylene glycol (PLGA-PEG) is a very good nano-carrier, which has been applied in the medical field. In this context, we studied the immunotherapy effect and potential mechanism of recombinant Amb a 1 (rAmb a 1)-loaded PLGA-PEG nanoparticles. A mouse allergic conjunctivitis model was established with Ambrosia artemisiifolia crude extract, and the nanoparticles were used for AIT through direct observation of conjunctival tissue, degranulation of mast cells in conjunctival tissue, serum-specific antibodies, cytokines and other assessment models. The treatment of nanoparticles enhanced the secretion of T-helper 1 (Th1) cytokine Interferon-gama (IFN-γ) and the production of immunoglobulin G (IgG)2a (IgG2a), inhibited the secretion of T-helper 2 (Th2) cytokine Interleukin (IL)-13 and IL-4 and the level of IgE. Especially, degranulation of mast cells and expression of mast cell protease-1 (MCP-1) in conjunctival tissue was reduced significantly. In this study, we proved that the nanoparticles prepared by rAmb a 1 and PLGA-PEG have an immunotherapy effect on allergic conjunctivitis in mice.